Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBELIX: Bevacizumab + XELOX in mCRC
NCT00577031Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2008
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Roche. Primary endpoint: Progression-Free Survival up to 5 years. Started Feb 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00577031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577031.